Christopher is a partner in the intellectual property team, based in our Boston office.
He focuses his practice on biotechnology patent preparation and prosecution across nucleic acid therapeutics (including both payloads and particle-based delivery modalities), immunotherapies, genomic technologies, diagnostics/prognostics, personalized medicine, microbiology, virology, and cell biology. He also routinely provides strategic IP counsel to biotech industry and academic clients on IP due diligence, domestic and international IP portfolio management, and has prepared non-infringement, invalidity, and freedom-to-operate opinions.
Prior to joining Withers, Chris was a patent attorney at several law firms and also served for four years as Director of Intellectual Property at Dicerna Pharmaceuticals, Inc., where he was responsible for managing, prosecuting, and growing the company's portfolio of RNAi-relevant patent applications through multiple stages of venture capital funding, partnering, collaborations, licensing, and due diligence, including procurement of broad claims of high value that protect the company's core drug platform.
Recent recognition
